PUBLISHED PROGRAMME FINDINGS
Programme experience, with its context.
Findings from 1,218 participants registered in East Singhbhum, Jharkhand, from 11 August 2025 to 30 September 2026. Source: published programme findings from the field implementation.
Programme evidence
Reach, continuity, and clinical outcomes
EpiCare supported continuing epilepsy care in East Singhbhum, Jharkhand. Published programme findings describe an observational cohort of 1,218 participants.
1,210 (99.3%)
Received at least one follow-up
Among all 1,218 registered participants
33 days
Median time to first contact
Among contacted participants; IQR 22–51 days
422/462 (91.3%)
Returned after an interruption
Among participants with a contact gap exceeding 90 days, during available follow-up
Reported seizures around six and twelve months
Assessments asked about seizures since the preceding visit. Participants entered at different times, so eligibility and assessment availability differed between windows.
| Assessment window | Eligible participants, n | Assessed, n (% eligible) | No interval seizures, n/N (% assessed) | Median reporting interval |
|---|---|---|---|---|
| Around six months | 994 | 793 (79.8%) | 593/793 (74.8%) | 35 days (IQR 29–47) |
| Around twelve months | 396 | 366 (92.4%) | 216/366 (59.0%) | 31 days (IQR 28–33) |
Zero reported interval seizures describes the period since the preceding visit, rather than continuous seizure freedom over six or twelve months.
Continuing care needs continued review
Among 330 participants assessed at both windows, 246 (74.5%) reported no interval seizures around six months and 190 (57.6%) around twelve months. These findings support attention to ongoing clinical review, medicine access, and treatment adjustment. The observational analysis describes programme experience; it does not establish a causal treatment effect.
How care was delivered
Telephone and in-person follow-up supported continuing contact. Medicine sources were reported at individual contacts, so a participant could contribute more than one record.
4,761/7,183 (66.3%)
Telephone contacts
Among contacts with recorded modality
2,422/7,183 (33.7%)
In-person contacts
Among contacts with recorded modality
3,384/8,576 (39.5%)
Medicines through ASHAs or CHOs
Among contacts reporting a medicine source
3,289/8,576 (38.4%)
Medicines through community health centres
Among contacts reporting a medicine source
1,207/8,576 (14.1%)
Medicines through private pharmacies
Among contacts reporting a medicine source
The recorded medicine-source category combines ASHAs and CHOs. Selected sources shown; percentages do not sum to 100%.
Early contact and re-engagement
Among 1,203 participants eligible for initial 90-day observation, 1,046 (86.9%) had first contact within 90 days. Eligibility required registration by 2 July 2026 and no recorded death through day 90.
Among 442 participants whose first interruption allowed a further 90 days of observation, 354 (80.1%) returned within that period. Another 20 interruptions began too late for this fixed-opportunity analysis.
Recorded clinical actions
Referral was recorded at 68 contacts involving 66 participants. Medication changes were recorded at 67 contacts involving 63 participants. Explicit responses were available at 1,927 and 1,915 contacts respectively. Action-field recording changed during implementation.
Medication-taking reports
Always taking antiseizure medication was reported by 611/811 (75.3%) six-month respondents and 272/376 (72.3%) twelve-month respondents.
Among 345 participants assessed at both windows, the paired change was −7.5 percentage points (95% CI −18.1 to 3.0), with clustering by participant and submitting account.
Mortality surveillance
Twenty-seven deaths (2.2%) were documented. Median recorded age was 31 years (IQR 24–40); median time from registration to death was 186 days (IQR 105–289). Actual dates were available for 25; report dates were used for two. Ascertainment was incomplete.
How to read these findings
- The cohort was observational and outreach-based, with no comparison group. Twelve-month eligibility was restricted to August 2025 registrants.
- No interval seizures refers to the preceding contact interval, not continuous seizure freedom throughout six or twelve months.
- In 330 paired assessments, the seizure-report change was −17.0 percentage points (95% CI −32.3 to −1.7). After provider-pattern exclusions, it was −11.5 (95% CI −25.6 to 2.5).
- Unavailable assessments, variable reporting intervals, self-report, and incomplete linkage of clinical actions affect interpretation.
- Author declarations and institutional details still require confirmation before wider citation. No journal publication or unrestricted participant-data access is asserted here.
Before you begin.
Plain answers on who the product is for, what the demonstration contains, and how to read the field findings.
Let's talk about your programme